| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10486283 | Value in Health Regional Issues | 2013 | 8 Pages |
Abstract
Using risk prediction for CAD based on a Japanese cohort with no history of cardiovascular events, the cost-effectiveness of pravastatin for primary prevention of CAD may not be cost-effective in populations at both low and high cardiac risk.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Yoshie MS, MPH, Shiro MD, PhD, Yoko M. MD, Hisashi DrPH, Koji MD, PhD,